Huang Y, Huang D, Geng Y, Fang S, Yang F, Wu C, Zhang H, Wang M, Zhang R, Wang X, Wu S, Cao J, Zhang R
Two patients may have identical BMI scores but very different waist measurements and health risks
Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, not yet licensed by the MHRA or EMA, with Phase 2 data showing substantial weight reduction over 48 weeks
In a sensitivity analysis restricted to placebo-controlled ALC monotherapy trials (4 studies), the pooled estimate also favored ALC (SMD 2.41, 95% CI 4.43 to 0.39
However, naturally produced GLP-1 has a very short half-lifeapproximately 2 to 3 minutesbecause it is rapidly degraded by the enzyme dipeptidyl peptidase-4 (DPP-4)
The incidence rate was however very small, meaning that any direct causality is hard to pin down